FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Issues Raised on 510(k) Change Guidance

[ Price : $8.95]

Five stakeholders raise concerns about an FDA draft guidance on when a new 510(k) should be submitted for a change to an existing ...

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Innovative Compounding Pharmacy and Valeant Pharmaceuticals.

Final Rule to Reflect Agency Organization Change

[ Price : $8.95]

Federal Register Final Rule: FDA issues a final rule to amend the regulations to reflect organization change in the agency and to ...

Comments Sought on Standardized Study Data Template

[ Price : $8.95]

Federal Register Notice: FDA establishes a public docket to collect comments related to a proposed Study Data Standardization Plan...

Clinical Hold Slapped on BioInvent Myeloma Drug

[ Price : $8.95]

FDA places a clinical hold on a BioInvent International Phase 2 study of the antibody BI-505 in patients with multiple myeloma.

Guidance on Non-inferiority Drug Effectiveness Studies

[ Price : $8.95]

FDA posts a guidance on Non-Inferiority Clinical Trials to Establish Effectiveness that discusses the appropriate use of such stud...

FDA Clears EOS Imaging Knee Software

[ Price : $8.95]

FDA clears an EOS Imaging 510(k) to market the kneeEOS software, an online 3D planning product software that uses weight-bearing 3...

FDA Approves Pediatric Use of Amgens Enbrel

[ Price : $8.95]

FDA approves an Amgen supplemental BLA for the expanded use of Enbrel (etanercept) to treat pediatric patients (ages 4-17) with ch...

FDA/CMS Heads Discuss Changing Evidence Standards

[ Price : $8.95]

FDA commissioner Robert Califf and CMS administrator Andrew Slavitt offer their perspectives on the two agencies changing approach...

FDA Guide on MDR Reporting

[ Price : $8.95]

FDA releases a final guidance on Medical Device Reporting (MDR) for Manufacturers that is intended to assist manufacturers with me...